Effects of nicotine and amphetamine on latent inhibition in human subjects

Psychopharmacology

Volumn 127, Issue 1, 1996, Pages 164-173

  Thornton, J C ^a   Dawe, S ^a   Lee, C ^a   Capstick, C ^a   Corr, P J ^a   Cotter, P ^a   Frangou, S ^a   Gray, N S ^a   Russell, M A H ^a   Gray, J A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amphetamine; Human subjects; Latent inhibition; Nicotine; Schizophrenia; Smoking

Indexed keywords

DEXAMPHETAMINE; NICOTINE; PLACEBO;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; LATENT INHIBITION; LEARNING; MALE; NORMAL HUMAN; NUCLEUS ACCUMBENS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 9544232550     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02805990     Document Type: Article

References (66)

1. Adler LE, Holler LJ, Griffith J, Waldo MC, Freedman R (1992) Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32:607-616
2. Adler LE, Hoffer LD, Wiser A, Freedman R (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150:1856-1861
3. Allan LM, Williams JH, Wellman NA, Tonin J, Taylor E, Rawlins JNP (1995). Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Person Individ Diff 19:893-902
4. Armitage AK, Dollery CT, George CF, Houseman TH, Lewis PJ, Turner DM (1975) Absorption and metabolism of nicotine from cigarettes. Br Med J 4:313-316
5. Baruch I, Hemsley DR, Gray JA (1988a) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598-606
6. Baruch I, Hemsley DR, Gray JA (1988b) Latent inhibition and "psychotic proneness in normal subjects. Person Individ Diff 8:777-784
7. Benowitz NL, Porchet H, Jacob P (1990) Pharmacokinetics, metabolism, and pharmacodynamics of nicotine. In: Wonnacott S, Russell MAH, Stolerman IP (eds) Nicotine psychopharmacology: molecular, cellular, and behavioural aspects. Oxford University Press, Oxford New York Tokyo, pp 112-151
8. Benwell MEM, Balfour DJK, Anderson JM (1988) Evidence that tobacco smoking increases the density of nicotine binding sites in human brain. J Neurochem 50:1243-1247
9. Brazell MP, Mitchell SN, Gray JA (1990) Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudateputamen. Neuropharmacology 29:1177-1185
10. Christison GW, Atwater GE, Dunn LA, Kilts CD (1988) Haloperidol enhancement of latent inhibition: relation to therapeutic action? Biol Psychiatry 23:746-749
11. Corrigall WA, Coen KM (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104:171-176
12. Corrigall WA, Franklin KB, Coen KM, Clarke PB (1992) The mesolimbic dopamine system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285-2S9
13. Dawe S, Gerada C, Russell MAH, Gray JA (1995) Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology 117:110-115
14. De Leon J, Dadvand M, Canuso C, While AO, Stanilla JK, Simpson GM (1995) Schizophrenia and smoking: an epidomiological survey in a state hospital. Am J Psychiatry 152:453-45
15. Dunn LA, Atwater GE, Kilts CD (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioural model of clinical drug action. Psychopharmacology 112:315-323
16. Ellenbroek BA, Cools (1990) Animal models with construct validity for schizophrenia. Behav Pharmacol 1:469-490
17. Erechefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR (1985) Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 29:635-646
18. Eysenck SBG, Eysenck HJ, Barrett P (1985) A revised version of the psychoticism scale. Person Individ Diff 6:21-29
19. Feldon J, Weiner I (1991) The latent inhibition model of schizophrenic attention disorder: haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 2:635-646
20. Feyerabend C, Ings RMJ, Russell MAH (1985) Nicotine pharmacokinetics and its application to intake from smoking. Br J Clin Pharmacol 1:239-247
21. Ginton A, Urca G, Lubow RE (1975) The effects of preexposure to a non-attended stimulus on subsequent learning: latent inhibition in adults. Bull Psychonom Soc 5:5-8
22. Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 14:1189-1194
23. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14: 1-20
24. Gray JA, Joseph MH, Hemsley DR, Young AMJ, Warburton EC, Boulenguez P et al. (1995) The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 71:19-31
25. Gray NS, Hemsley DR, Gray JA (1992a) Abolition of latent inhibition in acute but not chronic schizophrenics. Neurol Psychiatry Brain Res 1:83-89
26. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992b) Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology 107:425-430
27. 2 binding using SPET. Schizophr Res 17:95-107
28. Hughes JR, Hatsukami DK (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289-294
29. Hughes JR, Halsukami DK, Mitchell JE, Dahlgren LA (1986) Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143:993-997
30. Imperato A, Mulas A, Di Chiara G (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337-338
31. Jann MW, Saklad SR, Erechevsky L, Richards AL, Harrington CA, Davis CM (1986) Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 90:468-470
32. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y (1987) Comparison of tests used to distinguish smokers from nonsmokers. Am J Pub Health 77:1435-1438
33. Jones, GMM, Sahakian BJ, Warburton DM, Gray JA (1992) Effects of subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494
34. Joseph MH, Jones SH (1991) Latent inhibition and blocking: further consideration of their construct validity as animal models of schizophrenia. Commentary on Ellenbroek and Cools animal models with construct validity for schizophrenia. Behav Pharmacol 2:521-556
35. Joseph MH, Peters SL, Gray JA (1993) Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology 110:187-192
36. Joseph, MH, Peters, SL, Young AMJ, Warburton EC, Gray JA (1994) Animal studies on dopamine and disrupted latent inhibition: a model of cognitive deficit in schizophrenia. (Abstract) Schizophr Res 11:112
37. Killcross AS, Robbins TW (1993) Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology 110:479-489
38. Lohr JB, Flynn K (1992) Smoking and schizophrenia. Schizophr Res 8:93-102
39. Lubow RE (1989) Latent inhibition and conditioned attention theory. Cambridge University Press, Cambridge
40. Lubow RE, Moore AU (1959) Latent inhibition: the effects of non-reinforced pre-exposure to the conditioned stimulus. J Comp Physiol Psychol 52:415-419
41. Lubow RE, Ingberg-Sachs Y, Zalstein-Orda N, Gewirtz JC (1992) Latent inhibition in low and high "psychotic-prone" normal subjects. Person Individ Diff 13:563-572
42. Meddis R (1984) Statistics using ranks: a unified approach. Basil Blackwell, Oxford
43. Moran PM, Fischer T, Hitchcock J, Moser PC (1996) Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7:42-48
44. Norusis MJ (1993) SPSS for Windows: advanced statistics release 6.0. SPSS, Chicago
45. Peters SL, Joseph MH (1993) Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure. Behav Pharmacol 4:183-186
46. Pomerleau CS, Pomerleau OF (1992) Euphoriant effects of nicotine in smokers. Psychopharmacology 10:460-465
47. Porrino LJ, Lucignani G, Dow-Edwards D, Sokoloff L (1984) Correlation of dose-dependent effects of acute amphetamine on behaviour and local cerebral metabolism in rats. Brain Res 307:311-320
48. Russell MAH, Jarvis MJ, Jones G, Feyerabend C (1990) Nonsmokers show acute tolerance to subcutaneous nicotine. Psychopharmacology 102:56-58
49. Schmajuk NA, Lam Y-W, Gray JA (1996). Latent inhibition: a neural network approach. J Exp Psychol: [Anim Behav Proc] (in press)
50. Serra AMM (1995) Latent inhibition and the Kamin blocking effect in schizophrenia and schizotypy. Unpublished PhD thesis, University of London
51. Solomon PR, Staton DM (1982) Differential effects of microinjeclions of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus. Biol Psychiatry 17:743-756
52. Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981) Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16:519-537
53. Srivastava ED, Russell MAH, Feyerabend C, Masterson JG, Rhodes J (1991) Sensitivity and tolerance to nicotine in smokers and nonsmokers. Psychopharmacology 105:63-68
54. Swett C (1974) Drowsiness due to chlorpromazine in relation to cigarette smoking. Arch Gen Psychiatry 31:211-213
55. Wan SH, Malin SB, Azarnoff DL (1978) Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther 23:585-590
56. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced disruption of latent inhibition by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657-664
57. Weiner I (1990) Neural substrates of latent inhibition: the switching model. Psychol Bull 10:442-461
58. Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol. Psychopharmacology 91:248-253
59. Weiner I, Lubow RE, Feldon J (1981) Chronic amphetamine and latent inhibition. Behav Brain Res 2:285-286
60. Weiner I, Feldon J, Katz Y (1987a) Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav 26:241-246
61. Weiner I, Izraeli-Telerant A, Feldon J (1987b) Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine. Psychopharmacology 1:345-351
62. Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine in rats. Pharmacol Biochem Behav 30:871-878
63. Weiner I, Shofel A, Feldon J (1990) Disruption of latent inhibition by a low dose of amphetamine is antagonised by haloperidol and apomorphine. J Psychopharmacol 4:255
64. West R. Russell MAH (1988) Loss of acute tolerance and severity of cigarette withdrawal. Psychopharmacology 94:563-565
65. Williams JH, Wellman NA, Rawlins JNP, Geaney DP, Cowen PJ, Feldon J (1994) Haloperidol increases latent inhibition in high schizotypal subjects. Schizophr Res 11:1628, Poster 145
66. Young AMJ, Joseph MH, Gray JA (1993) Latent inhibition of conditioned dopamine release in rat nucleus accumbens. Neuroscience 54:5-9